Viewing nowCombinationCoaprovell Tablets 150/12.5 mg
Irbesartan 150mg · Hydrochlorothiazide 12.5mg
Tablet · Prescription medication · Combination
Handok Co., Ltd.

MFDS item code 200702137 · Notified 2007.02.16 · Insurance code 652101260
Treatment of essential hypertension
This medication is used in cases where blood pressure is not adequately controlled with monotherapy in patients with essential hypertension, or as an initial treatment requiring combination therapy in moderate to severe hypertension to achieve target blood pressure. In other words, it helps improve blood pressure in individuals who have difficulty controlling their blood pressure.
Administer this medicine once daily, regardless of meals. Titration of each component (irbesartan and hydrochlorothiazide) is recommended. ○ Adults 1. Patients whose blood pressure is not adequately controlled with monotherapy - For patients whose blood pressure is not adequately controlled with irbesartan 150 mg or hydrochlorothiazide alone, administer 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg or irbesartan 150 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 25 mg once daily. Doses exceeding irbesartan 300 mg/hydrochlorothiazide 25 mg are not recommended. This medicine may be administered in combination with other antihypertensive agents if needed. 2. When this medicine is to be used as initial therapy in patients with moderate or severe hypertension (stage 2), treatment should be individualized by taking into consideration baseline blood pressure, the target blood pressure, and the expected increase in the likelihood of achieving the treatment target compared with a single agent. The usual starting regimen is 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily; if blood pressure control is needed, the dose may be increased after 1 ~ 2 weeks to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg. Use of this medicine as initial therapy is not recommended in patients with intravascular volume depletion. ○ Patients with renal impairment Because of the hydrochlorothiazide component, this medicine is not recommended for patients with severe renal impairment (creatinine clearance〈 30 mL/min). Loop diuretics are preferred in this patient population. No dose adjustment is necessary in patients with renal impairment whose creatinine clearance is 30 mL/min or greater. ○ Patients with volume depletion If sodium and/or fluid has been depleted, the imbalance should be corrected before administering this medicine. ○ Patients with hepatic impairment This medicine should not be used in patients with severe hepatic impairment. Thiazide drugs should be used with caution in patients with hepatic impairment. No dose adjustment is necessary in patients with mild ~ moderate hepatic impairment. ○ Elderly patients No dose adjustment is necessary for elderly patients.
○ Children Children and adolescents under 18 years: The safety and efficacy of this medicine have not been established.
This medication can cause serious harm to the fetus if taken during pregnancy, particularly during the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Women who are pregnant or may become pregnant, breastfeeding individuals, and those allergic to this medication or its components should not take it. Patients with severely impaired kidney function, anuria, and those with certain liver conditions should also refrain from using this medication. Patients with a history of angioedema or those with genetic disorders related to lactose intolerance should exercise caution. Diabetic patients with impaired kidney function, or diabetic nephropathy patients taking ACE inhibitors should avoid using this medication together. Patients with specific conditions such as hypotension, kidney disease, liver impairment, heart valve issues, or angle-closure glaucoma should use this medication with caution. The hydrochlorothiazide component can react sensitively to sunlight, potentially increasing the risk of skin cancer; thus, exposure to sunlight should be avoided while on this medication, and skin condition should be monitored frequently. Taking this medication may cause dizziness, fatigue, nausea, changes in urination, etc., and may lead to changes in kidney function or electrolyte levels in blood tests, necessitating regular monitoring. Dizziness or fatigue can occur while driving or operating machinery; therefore, caution is advised. Although this medication lowers blood pressure, it can exacerbate hypotension in cases of dehydration or sodium deficiency; if these conditions are present, you should inform your healthcare provider beforehand. This medication may affect potassium and sodium levels in the blood, so regular blood tests are required, especially when used with potassium supplements or potassium-sparing diuretics. If there is a sudden onset of eye pain or vision changes, there is a risk of acute angle-closure glaucoma, and immediate medical attention should be sought. This medication can interact with other antihypertensives, lithium, NSAIDs, etc., so ensure to inform your healthcare provider of any other medications you are taking. Pregnant or breastfeeding women should not take this medication, and safety in children or adolescents has not been established, so it is not recommended. Elderly individuals may be more sensitive to this medication; therefore, caution is necessary when taking it. In case of overdose, symptoms such as hypotension, electrolyte imbalance, or dehydration may occur, requiring immediate medical attention and treatment. This medication should be kept out of reach of children, stored in its original container, and transferring it to another container may lead to quality degradation or misuse.
Dizziness, fatigue, nausea, vomiting, abnormal urination, elevated BUN, increased creatine kinase, elevated creatinine, orthostatic dizziness, headaches, fainting, hypotension, tachycardia, edema, flushing, coughing, diarrhea, dyspepsia, taste disturbances, jaundice, hepatitis, abnormal liver function, sexual dysfunction, changes in libido, kidney function impairment, limb edema, arthralgia, myalgia, tinnitus, angioedema, rash, urticaria, hyperkalemia, decreased serum potassium, decreased serum sodium, angioedema, herpes zoster, colon cancer, hematoma, weakness, dyspepsia, tinnitus, myalgia, increased plasma creatine kinase, tachycardia, hepatitis, liver function abnormalities, renal failure, depression, sleep disorders, orthostatic hypotension, arrhythmia, aplastic anemia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, leukopenia, thrombocytopenia, respiratory distress, acute respiratory distress syndrome, pancreatitis, loss of appetite, constipation, gastric irritation, sialadenitis, loss of appetite, interstitial nephritis, kidney function disorders, jaundice, transient blurred vision, xanthopsia, acute angle closure glaucoma, acute myopia, choroidal effusion, weakness, muscle cramps, anaphylactoid reactions, toxic epidermal necrolysis, necrotizing vasculitis, lupus erythematosus-like skin erythema, reactivation of lupus erythematosus-like skin erythema, photosensitivity reactions, rash, urticaria, fever, electrolyte imbalance, hyperuricemia, diabetes, hyperglycemia, elevated cholesterol and triglycerides, lip cancer, hypoglycemia, abdominal pain, nausea, diarrhea
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is recommended to maintain a storage temperature between 1°C and 30°C at room temperature.
Pink, biconvex, oval film-coated tablets with an imprint of a heart shape on one side and the number '2875' on the other side
3X10 tablets/blister, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationIrbesartan 150mg · Hydrochlorothiazide 12.5mg
Tablet · Prescription medication · Combination
Handok Co., Ltd.
CombinationIrbesartan 300mg · Hydrochlorothiazide 12.5mg
Tablet · Prescription medication · Combination
Handok Co., Ltd.
CombinationIrbesartan 150mg · Hydrochlorothiazide 12.5mg
Tablet · Prescription medication · Combination
Samchundang Pharmaceutical Co., Ltd.
Irbesartan 150mg · Hydrochlorothiazide 12.5mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
Irbesartan 150mg · Hydrochlorothiazide 12.5mg
Tablet · Prescription medication · Combination
Dongwha Pharmaceutical Co., Ltd.
CombinationIrbesartan 150mg · Hydrochlorothiazide 12.5mg
Tablet · Prescription medication · Combination
Myungin Pharmaceutical Co., Ltd.
CombinationIrbesartan 300mg · Hydrochlorothiazide 12.5mg
Tablet · Prescription medication · Combination
Myungin Pharmaceutical Co., Ltd.
CombinationIrbesartan 150mg · Hydrochlorothiazide 12.5mg
Tablet · Prescription medication · Combination
Ahn-Guk Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.